Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives $25.71 Consensus Target Price from Analysts

Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) has received a consensus rating of "Buy" from the nine research firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $25.71.

KYTX has been the topic of several research reports. Wells Fargo & Company cut their target price on Kyverna Therapeutics from $44.00 to $24.00 and set an "overweight" rating on the stock in a research report on Friday, November 15th. UBS Group started coverage on Kyverna Therapeutics in a research note on Thursday, October 10th. They issued a "buy" rating and a $13.00 price objective on the stock. Rodman & Renshaw began coverage on shares of Kyverna Therapeutics in a research report on Wednesday, October 9th. They set a "buy" rating and a $16.00 target price for the company. HC Wainwright reduced their price target on shares of Kyverna Therapeutics from $7.00 to $6.00 and set a "neutral" rating on the stock in a research report on Wednesday, November 20th. Finally, RODMAN&RENSHAW raised shares of Kyverna Therapeutics to a "strong-buy" rating in a research report on Wednesday, October 9th.

Kyverna Therapeutics Stock Up 6.3 %

KYTX traded up $0.34 during midday trading on Friday, hitting $5.77. The company's stock had a trading volume of 296,981 shares, compared to its average volume of 453,515. Kyverna Therapeutics has a 52-week low of $3.92 and a 52-week high of $35.06. The firm has a 50-day moving average price of $5.03 and a two-hundred day moving average price of $7.79.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last released its earnings results on Wednesday, November 13th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.81) by $0.01. The company had revenue of $0.01 million during the quarter. On average, research analysts expect that Kyverna Therapeutics will post -3.29 earnings per share for the current year.

Institutional Trading of Kyverna Therapeutics

Large investors have recently modified their holdings of the business. FMR LLC acquired a new stake in Kyverna Therapeutics during the 3rd quarter valued at approximately $33,000. Creative Planning bought a new stake in shares of Kyverna Therapeutics in the third quarter worth $54,000. Jacobs Levy Equity Management Inc. acquired a new stake in Kyverna Therapeutics in the third quarter valued at $97,000. Federated Hermes Inc. acquired a new position in Kyverna Therapeutics during the 2nd quarter worth $120,000. Finally, BNP Paribas Financial Markets increased its position in shares of Kyverna Therapeutics by 2,166.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 27,197 shares of the company's stock worth $133,000 after purchasing an additional 25,997 shares during the last quarter. 18.08% of the stock is currently owned by institutional investors and hedge funds.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.